Comparison · NCT02957682-deaths
Alirocumab 75 Q2W/Up150 Q2W vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Alirocumab 75 Q2W/Up150 Q2W vs Placebo: deaths from any cause. Trial comparisons, record NCT02957682-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02957682-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0156 | 0.00979 | 0.0249 | wilson | |
| Risk in group 2 | 0.0221 | 0.0149 | 0.0327 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0065 | -0.0186 | 0.00524 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.706 | 0.382 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.702 | 0.375 | 1.31 | log | |
| Number needed to treat, for one fewer death from any cause on Alirocumab 75 Q2W/Up150 Q2W than on Placebo | 154 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Alirocumab 75 Q2W/Up150 Q2W | Participants received SC injections of alirocumab at a dose of 75 milligrams (mg) Q2W and up-titrated to 150 mg Q2W at Week 12 in a blinded fashion (if LDL-C ≥ 50 mg/dL at Week 8) up to 94 weeks. | 17 | 1,087 | EG001 |
| Group 2 | Placebo | Participants received subcutaneous (SC) injections of placebo matched to alirocumab every 2 weeks (Q2W) up to 94 weeks. | 24 | 1,084 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 96) regardless of seriousness or relationship to investigational product (IP).
Source ClinicalTrials.gov
Trial
- Title
- Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
- NCT number
- NCT02957682
- Phases
- PHASE4
- Conditions
- Hypercholesterolemia
- Interventions
- Praluent (Alirocumab), Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2021-05-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02957682?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02957682-deaths